European best practice guidelines for the management of anaemia in patients with chronic renal failure

Nephrology Dialysis Transplantation

Volumn 14, Issue SUPPL. 5, 1999, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750127438     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (576)

1. Committee to advise the public health service on clinical practice guidelines, Institute of Medicine. In: Field MJ, Lohr KN, eds. Clinical practice guidelines: directions for a new program. National Academy Press, Washington, DC: 1990
2. Anonymous. Attributes to guide the development and evaluation of practice parameters/guidelines. American Medical Association/Specialty Society Practice Parameters Partnership: 1996: 1-10
3. Good practice clinical guidelines. NHS Executive, London: 1996
4. Thomson R, Lavender M, Madhok R. How to ensure that guidelines are effective. Br Med J 1995; 311: 237-242
5. Treatment of patients with renal failure: recommended standards and audit measures. Renal Association and Royal College of Physicians, London: 2nd edition 1997
6. UKRENALREG 1998. The First Annual Report of the UK Renal Registry. UK Renal Registry, Bristol: 1998
7. US Department of Health and Social Services, Public Health Service and Agency for Health Care Policy and Research. Acute pain management: operative or medical procedures and trauma. Agency for Health Policy and Research (AHCPR publication 92-0038), Rockville, MD: 1992
8. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD) Kidney Int 1985; 28: 1-5
9. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989; 35: 134-148
10. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997; 51: 622-630
11. Parker PA, Izard MW, Maher JF. Therapy of iron deficiency anemia in patients on maintenance dialysis. Nephron 1979; 23: 181-186
12. Potasman I, Better OS. The role of secondary hyperparathyroidism in the anemia of chronic renal failure. Nephron 1983; 33: 229-231
13. Kaiser L, Schwartz KA. Aluminium-induced anemia. Am J Kidney Dis 1985; 6: 348-352
14. Hampers CL, Streiff R, Nathan DG et al. Megaloblastic hematopoiesis in uremia and in patients on long-term hemodialysis. N Engl J Med 1967; 276: 551-554
15. Eschbach JW, Funk D. Adamson J et al. Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 1967; 276: 653-658
16. Horina JH, Schwaberger G, Brussee H et al. Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin. Nephrol Dial Transplant 1993; 8: 1219-1222
17. Robertson HT, Haley NR, Guthrie M et al. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis 1990; 15: 325-332
18. Braumann KM, Nonnast-Daniel B, Boning D et al. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron 1991; 58: 129-134
19. The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-contolled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991; 18: 50-59 (RCT)
20. Mayer G, Thum J, Cada EM et al. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988; 34: 525-528
21. Wizemann V, Schäfer R, Kramer W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 1993; 64: 202-206
22. Harnett JD, Foley RN, Kent GM et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884-890
23. Wizemann V, Kaufmann J, Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992; 62: 161-165
24. Cannella G, La Canna G, Sandrini M et al. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol 1990; 34: 272-278
25. Macdougall IC, Lewis NP, Saunders MJ et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990; 335: 489-493
26. Pascual J, Teruel JL, Moya JL et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280-287
27. Wolcott DL, Marsh JET, La Rue A et al. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989; 14: 478-485
28. Eschbach JW, Adamson JW. Recombinant human erythropoietin: implications for nephrology. Am J Kidney Dis 1988; 11: 203-209
29. Ramirez G, Bittle PA, Sanders H et al. The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin. J Clin Endocrinol Metab 1994; 78: 63-69
30. Schaefer RM, Kokot F, Heidland A. Impact of recombinant erythropoietin on sexual function in hemodialysis patients. Contrib Nephrol 1989; 76: 273-282
31. Sobh MA, Abd el Hamid IA, Atta MG, Refaie AF. Effect of erythropoietin on sexual potency in chronic haemodialysis patients: a preliminary study. Scand J Urol Nephrol 1992; 26: 181-185
32. Gafter U, Kalechman Y, Orlin JB et al. Anemia of uremia is associated with reduced in vitro cytokine secretion: immunopotentiating activity of red blood cells. Kidney Int 1994; 45: 224-231
33. Vanholder R, Van Biesen W, Ringoir S. Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 1993; 44: 208-214
34. Scigalla P, Bonzel KE, Bulla M et al. Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease. Contrib Nephrol 1989; 76: 227-241
35. Evans RW, Rader B, Manninen DL, Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 263: 825-830
36. Lowrie EG, Huang WH, Lew NL, Yiu Y. The relative contribution of measured variables to death risk among hemodialysis patients. In: Friedman EA, ed. Death on hemodialysis: preventable or inevitable? Kluwer Academic Publishers, Boston, MA: 1994: 121-141
37. Opelz G, Vanrenterghem Y, Kirste G et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 1997; 63: 964-967
38. Vella JP, O'Neill D, Atkins N et al. Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant 1998; 13: 2027-2032
39. Adamson JW, Eschbach JW. Management of the anaemia of chronic renal failure with recombinant erythropoietin. QJM 1989; 73: 1093-1101
40. Eschbach JW. The future of r-HuEPO. Nephrol Dial Transplant 1995; 10(suppl 2): 96-109
41. Winearls CG, Oliver DO, Pippard MJ et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-1178
42. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78
43. Grützmacher P, Scheuermann E, Löw I et al. Correction of renal anaemia by recombinant human erythropoietin: effects on myocardial function. Contrib Nephrol 1988; 66: 176-184
44. Eschbach JW, Haley NR, Egrie JC, Adamson JW. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int 1992; 42: 407-416
45. Valderrábano F. Erythropoietin in chronic renal failure. Kidney Int 1996; 50: 1373-1391
46. Madore F, Lowrie EG, Brugnara C et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 1997; 8: 1921-1929
47. Collins A, Ma J, Ebben J. Hospital length of stay is associated with hematocrit level. J Am Soc Nephrol 1997; 8: 190A (abstract)
48. Collins A, Ma J, Ebben J. Patient survival is associated with hematocrit (HCT) level. J Am Soc Nephrol 1997; 8: 190A (abstract)
49. Gahl GM, Eckardt K-U. Erythropoietin 1997: a brief update. Perit Dial Int 1997; 17 (suppl 2): S84-S90
50. Burke JR, on behalf of the Australian and New Zealand Paediatric Nephrology Association. Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Pediatr Nephrol 1995; 9: 558-561
51. Jabs K, Harmon WE. Recombinant human erythropoietin therapy in children on dialysis. Adv Renal Replacement Therapy 1996; 3: 24-36
52. Jabs K. The effects of recombinant human erythropoietin on growth and nutritional status. Pediatr Nephrol 1996; 10: 324-327
53. Low CL, Bailie GR, Rasmussen R, Eisele G. Optimal and cost effective erythropoietin use in hemodialysis patients. Pharmacotherapy 1996; 16: 505 (abstract)
54. Ismail N, Becker BN. An opportunity to intervene: erythropoietin for the treatment of anaemia in pre-dialysis patients. Nephrol Dial Transplant 1998; 13: 14-17
55. Glennie JL, Risbey D. Erythropoietin outcomes assessment: linking clinical and economic parameters. Can J Hosp Pharm 1997; 50: 69-76
56. Thamer M, Richard C, Ray NF et al. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states. Am J Kidney Dis 1996; 28: 235-249
57. Appendix A. In: Lee GR et al., eds. Wintrobe's clinical hematology. Lea & Febiger, Philadelphia PA: 9th edition 1993: 2303
58. Hakim RM, Lazarus JM. Biochemical parameters in chronic renal failure. Am J Kidney Dis 1988; 11: 238-247
59. Chandra M, Clemons GK, McVicar MI. Relation of serum erythropoietin levels to renal excretory function: evidence for lowered set point for erythropoietin production in chronic renal failure. J Pediatr 1988; 113: 1015-1021
60. McGonigle RJS, Boineau FG, Beckman B et al. Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anemia in children with renal disease. J Lab Clin Med 1985; 105: 449-458
61. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
62. Ishimura E, Nishizawa Y, Okuno S et al. Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J Nephrol 1998; 11: 83-86
63. Hillman RS, Finch CA. Clinical approach anemia. In: Hillman RD and Finch CA, eds. Red cell manual. F. A. Davis Company, Philadelphia PA: 5th edition 1985: 24
64. Hutchinson FN, Jones WJ. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease. Am J Kidney Dis 1997; 29: 651-657
65. Loge JP, Lange RD, Moore CV. Characterization of the anemia associated with chronic renal insufficiency. Am J Med 1958; 24: 4-18
66. Gokal R, Weatherall DJ, Bunch C. Iron induced increase in red cell size in haemodialysis patients. QJM 1979; 48: 393-401
67. Ifudu O, Dawood M, Friedman EA. Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure. Nephron 1997; 77: 315-318
68. Charles G, Lundin AP, III, Delano BG et al. Absence of anemia in maintenance hemodialysis. Int J Artif Organs 1981; 4: 277-279
69. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989; 14: 14-18
70. Auer J, Simon G, Stevens J et al. Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int 1992; 12: 40-42
71. Walls J. Haemoglobin - is more better? Nephrol Dial Transplant 1995; 10: 56-61
72. Beuerstein KM, Nissenson AR, Port FK et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773
73. López-Gómez JM, Jofre R, Moreno F et al. Quality of life in predialysis chronic renal failure (CRF) patients: effect of rHuEPO therapy. Nephrology 1997; 2 [suppl 1]: s309 (abstract)
74. Moreno F, Aracil FJ, Pérez R, Valderrábano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996; 27: 548-556
75. Essink-Bot ML, Krabbe PFM, Van Agt HME, Bonsel GJ. NHP or SIP a comparative study in renal insufficiency associated anemia. Qual Life Res 1996; 5: 91-100
76. Parsons DS, Harris DCH. A review of quality of life in renal failure. Pharmacoeconomics 1997; 12: 140-160
77. Consensus Development Conference Panel. Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Ann Intern Med 1994; 121: 62-70
78. Guthrie M, Cardenas D, Eschbach JW et al. Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol 1993; 39: 97-102
79. Fellner SK, Lang RM, Neumann A et al. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 1993; 44: 1309-1315
80. Löw-Friedrich I, Grützmacher P, März W et al. Long-term echocardiographic examinations in chronic hemodialysis patients substituted with recombinant human erythropoietin. Blood Purif 1990; 8:272-278
81. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4
82. Jones MA, Kingswood JC, Dallyn PE, Sharpstone P. Haemodynamic changes measured by transthoracic bioimpedance during treatment with recombinant erythropoietin. Clin Exp Hypertens 1996; 18: 51-64
83. Lim P-S, Yeh C-H, Hung T-S. Effects of recombinant erythropoietin on echocardiographic findings in elderly dialysis patients. Nephrology 1997; 3: 149-154
84. Foley RN, Parfrey PS. Commentary: cardiomyopathy of anemia and the potential of erythropoietin. Perit Dial Int 1997; 17: 117-118
85. Choi EJ, Song HC, Jin DC et al. The effects of recombinant human erythropoietin (r-HuEPO) therapy on exercise capacity and quality of life in patient with end stage renal failure. Nephrol Dial Transplant 1997; 12: A191 (abstract)
86. Meierhenrich R, Jedicke H, Voigt A, Lange H. The effect of erythropoietin on lactate, pyruvate and excess lactate under physical exercise in dialysis patients. Clin Nephrol 1996; 45: 90-96
87. Díez JJ, Iglesias P, Sastre J et al. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoetin therapy in CARD patients. Nephron 1996; 74: 548-554
88. Lawrence IG, Price DE, Hewlett TA et al. Erythropoietin and sexual dysfunction. Nephrol Dial Transplant 1997; 12: 741-747
89. Tarng DC, Huang TP, Doong TI. Improvement of nutritional status in patients receiving maintenance haemodialysis after correction of renal anemia with recombinant human erythropoeitin. Nephron 1998; 78: 253-259
90. Bárány P. Endocrinology and PD: optimal treatment of anemia in peritoneal dialysis patients. Perit Dial Int 1996; 16 [suppl 1]: s260-s266
91. Speia S, Pangakos E, Askepidis N et al. Effect of erythropoietin treatment on insulin resistance in hemodialysis patients. Nephrol Dial Transplant 1996; 11: A269 (abstract)
92. Utas C, Kelestimur F, Oymak O et al. Hypothalamo-pituitary axis in chronic renal failure patients on erythropoietin treatment. Nephrol Dial Transplant 1996; 11: A269 (abstract)
93. Steffensen G, Aunsholt NA, Povlsen JV. Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppresssion without affecting the distribution of peripheral blood mononuclear cell subpopulations. Clin Nephrol 1996; 45: 98-103
94. Lovcic V, Milutinovic S, Bubic LJ, Mazuran R. Erythropoietin-induced immunoregulation in dialysis PTS is independent of hemoglobin rise. Nephrol Dial Transplant 1997; 12: A192 (abstract)
95. Birmingham DJ, Shen XP, Hartman JA et al. Effect of chronic human recombinant erythropoietin therapy on antibody response to immunization in chronic hemodialysis patients. Kidney Int 1996; 50: 543-549
96. Huraib S, Abu-Aisha H, Al-Momen A et al. Effect of recombinant human erythropoietin on lymphocyte phenotyping and phagocyte activity in hemodialysis patients. Am J Kidney Dis 1997; 29: 866-870
97. Shurtz-Swirski R, Kristal B, Shkolnik T et al. Short-term effect of erythropoietin on T-cell mitogenic proliferation in chronic renal failure patients. Nephron 1996; 72: 27-29
98. Marrades RM, Alonso J, Roca J et al. Cellular bioenergetics after erythropoietin therapy in chronic renal failure. J Clin Invest 1996; 97: 2101-2110
99. Wong PN, Mak SK, Lo KY et al. The effect of recombinant human erythropoietin therapy on serum albumin in CAPD patients. J Am Soc Nephrol 1997; 8: 276A (abstract)
100. Mayer G, Hörl WH. Cardiovascular effects of increasing hemoglobin in chronic renal failure. Am J Nephrol 1996; 16: 263-267
101. Portolés J, Torralbo A, Martin P et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548
102. Churchill DN, Muirhead N, Goldstein M et al. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 1995; 43: 184-188
103. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998; 13: 1642-1644
104. Morduchowicz G, Boner G. Hospitalizations in dialysis end-stage renal failure patients. Nephron 1996; 73: 413-416
105. Revicki DA, Brown RE, Feeny DH et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548-554 (RCT)
106. Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61
107. Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998; 32 [suppl 4]: s133 s141
108. Möcks J, Franke W, Ehmer B et al. Analysis of safety database for long-term epoetin-beta treatment. A meta-analysis covering 3697 patients. In: Koch KM and Stein G, eds. Pathogenetic and therapeutic aspects of chronic renal failure. 12. Marcel Dekker Inc., New York: 1997: 163-179
109. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-290
110. Khan IH, Catto GRD, Edward N, Macleod AM. Death during the first 90 days of dialysis: a case control study. Am J Kidney Dis 1995; 25: 276-280
111. Ritz E, Zeier M, Schneider P, Jones E. Cardiovascular mortality of patients with polycystic kidney disease on dialysis: is there a lesson to learn? Nephron 1994; 66: 125-128
112. Levin A, Singer J, Thompson CR et al. Prevalent left ventricular hypertrophy in the preanalysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 7: 347-354
113. Greaves SG, Gamble GD, Collins JF et al. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kidney Dis 1994; 24: 768-776
114. London GM, Fabiani F, Marchais SJ et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 1987; 31: 973-980
115. Silberberg JS, Rahal DP, Patton DR, Sniderman AD. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 1989; 64: 222-224
116. Garcia DL, Anderson S, Rennke HG, Brenner BM. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 1998; 85: 6142-6146
117. Brown CD, Friedman EA. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients. Am J Nephrol 1990; 10: 29-33
118. Abraham PA, Opsahl JA, Rachael KM et al. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 1990; 10: 128-136 (RCT)
119. Eschbach JW, Kelly MR, Haley NR et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158-163
120. Lim VS, DeGowin RL, Zavala D et al. Recombinant human erythropoietin treatment in pre-dialysis patients: a double-blind placebo-controlled trial. Ann Intern Med 1989; 110: 108-114 (RCT)
121. Kleinman KS, Schweitzer SU, Perdue ST et al. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis 1989; 14: 486-495 (RCT)
122. Koch KM, Koene RAP, Messinger D et al. The use of epoelin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol 1995; 44: 201-208
123. Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and renal function in predialytic uremic patients. Nephron 1992; 60: 390-396
124. Sugino N, Hirasawa Y, Maeda K et al. Renal function of predialysis patients treated with recombinant erythropoietin (r-HuEPO). Nephrol Dial Transpl 1997; 12: A96 (abstract)
125. Krmar RT, Gretz N, Klare B et al. Renal function in predialysis children with chronic renal failure treated with erythropoietin. Pediatr Nephrol 1997; 11: 69-73
126. Roth D, Schulman G, Steinman TI et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 24: 777-784 (RCT)
127. Kuriyama S, Tomonari H, Yoshida H et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185
128. Minetti L. Erythropoietin treatment in renal anemia. How high should the target hematocrit be? J Nephrol 1997; 10: 117-119
129. Ritz E, Amann K. Optimal haemoglobin during treatment with recombinant human erythropoietin. Nephrol Dial Transplant 1998; 13 [suppl 2]: 16-22
130. Collins AJ, Keane WF. Higher haematocrit levels: do they improve patient outcomes, and are they cost effective? Nephrol Dial Transplant 1998; 13: 1627-1629
131. Nissenson AR. Optimal hematocrit for hemodialysis. Curr Opin Nephrol Hypertens 1997; 6: 524-527
132. Muirhead N, Bargman J, Burgess E et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995; 26: S1-S24 (RCT)
133. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990; 300: 573-578 (RCT)
134. Levin NW, Lazarus JM, Nissenson AR. Maximizing patient benefits with epoetin alfa therapy. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure an interim report. Am J Kidney Dis 1993; 22 [suppl 1]: 3-12
135. Ifudu O, Paul H, Mayers JD et al. Pervasive failed rehabilitation in center-based maintenance hemodialysis patients. Am J Kidney Dis 1994; 23: 394-400
136. Erythropoietin. In: Disney APS, ed. Sixteenth report of the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Woodville, Adelaide, South Australia: 1993: 130-135
137. McMahon LP, Johns JA, McKenzie A et al. Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 1992; 7: 1199-1206 (RCT)
138. McMahon LP, Dawborn JK. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 1992; 12: 162-169 (RCT)
139. +, pH, and different haemoglobin levels on maximal exercise performance in haemodialysis patients. Nephrology 1997; 2: S304 (abstract) (RCT)
140. Mason K, Skinner S, Sangkabutra T et al. Effects of erythropoietin on cardiac mass and function, ambulatory blood pressure and blood volumes at comparative levels of haemoglobin. Nephrology 1997; 2: S304 (abstract) (RCT)
141. Mason K, McMahon LP. Normalization of haemoglobin in haemodialysis patients: a comparative study. Nephrology 1997; 2: S305 (abstract) (RCT)
142. Suzuki M, Tsutsui M, Yokoyama A, Hirasawa Y. Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities. Anif Organs 1995; 19: 1258-1261
143. Bonelli C, Alvarez S, Alsina M, Brana D. Search of a good hematocrit (H) for patients (P) with a chronic renal insufficiency in hemodialysis. International Congress of Nephrology, Madrid, Spain, July, 1995: 507 (abstract)
144. Eschbach JW, Glenny R, Robertson T et al. Normalizing the hematocrit (HCT) in hemodialysis patients (HDP) with EPO improves quality of life (Q/L) and is safe. J Am Soc Nephrol 1993; 4: 425 (abstract)
145. Riedel E, Hampl H, Nündel M, Bosch J. Total correction of renal anemia improves malnutrition and amino acid (AA) metabolism in hemodialysis (HD) patients. J Am Soc Nephrol 1996; 7: 1462 (abstract)
146. Bárány P, Svedenhag J, Katzarski KJ et al. Physiological effects of correcting anemia in hemodialysis patients (HD pts) to a normal HB. J Am Soc Nephrol 1996; 7: 1472 (abstract)
147. Benz RL, Pressman MR, Hovick ET, Peterson DD. Relationship between anemia of chronic renal failure (ACRE) and sleep, sleep disorders, and daytime alertness: benefits of normalizing hematocrit (The Sleepo Trial). J Am Soc Nephrol 1996; 7: 1473 (abstract)
148. Mak RHK. Human recombinant erythropoietin (EPO) corrects insulin resistance and hyperlipidemia in patients on peritoneal dialysis (PD). J Am Soc Nephrol 1996; 7: 1490 (abstract)
149. Nissenson AR, Pickett JL, Theberge DC et al. Brain function is better in hemodialysis (HD) patients (PTS) when hematocrit (HCT) is normalized with erythropoietin (rHuEPO). J Am Soc Nephrol 1996; 7: 1459 (abstract)
150. Avram MM, Sreedhara R, Batish R et al. Characteristics of very long-term survivors on hemodialysis (HD); survival up to 30 years. J Am Soc Nephrol 1996; 7: 1437 (abstract)
151. Hayashi T, Shoji T, Okada N et al. To see the effect on circadian blood pressure variation and cardiac function in predialysis patients when hematocrit is normalized to 40% following recombinant human erythropoietin. Nephrology 1997; 3: S304 (abstract)
152. Valderrábano F. Data from the collaborative Spanish multicentre study of quality of life during progressive normalization of haemoglobin in 152 haemodialysis patients. Presented at the 2nd European Epoetin Symposium, 'Optimizing Anaemia Therapy in CRF', Crete, 17 19 April, 1998
153. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590 (RCT)
154. Danielsen B. Data from the Scandinavian Multicentre controlled study of normalization of the haemoglobin in 425 uraemic patients. Presented at the 2nd European Epoetin Symposium, 'Optimizing Anaemia Therapy in CRF', Crete, 17-19 April, 1998 (RCT)
155. Parfrey PS. Data from the Canadian multicentre controlled study of normalization of the haemoglobin in 76 patients with normal LV mass at beginning of trial. Presented at the 2nd European Epoetin Symposium, 'Optimizing Anaemia Therapy in CRF', Crete, 17-19 April, 1998 (RCT)
156. Nagao K, Tsuchihashi K, Ura N et al. Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Can J Cardiol 1997; 13: 747-53
157. Paulitschke M, Hampl H, Lerche D et al. Effects of total correction of renal anemia in hemodialysis patients by rhEPO therapy on rheology of whole blood and red blood cells. Nephrol Dial Transplant 1997; 12: A193 (abstract)
158. Junor BJR. Hematocrit above 30% in continuous ambulatory peritoneal dialysis patients treated with erythropoietin is harmful. Perit Dial Int 1993; 13: S535-S537
159. Shinaberger JH, Miller JH, Gardner PW. Erythropoietin alert: risks of high hematocrit hemodialysis. ASAIO Trans 1988; 34: 179-184
160. Raine AEG. Hypertension, blood viscosity and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988; 1: 97-99
161. Wood JH, Kee DB. Hemorheology of the cerebral circulation in stroke. Stroke 1985; 16: 765-772
162. Crowell JW, Smith EE. Determinant of the optimal hematocrit. J Appl Physiol 1967; 22: 501-504
163. Kusunoki M, Kimura K, Nakamura M et al. Effects of hematocrit variations on cerebral blood flow and oxygen transport on ischemic cerebrovascular disease. J Cereb Blood Flow Metab 1981; 1: 413-417
164. Von Kummer R, Scharf J, Back T et al. Autoregulatory capacity and the effect of isovolemic hemodilution on local cerebral blood. Stroke 1988; 23: 594-597
165. Hino A, Ueda S, Mizukawa N et al. Effects of hemodilution on cerebral hemodynamics and oxygen metabolism. Stroke 1992; 23: 423-426
166. Hampl H, Paulitschke M, Lerche D et al. Improved rheology of the newly generated RBC population as a result of rh-erythropoietin therapy (rhEPO). J Am Soc Nephrol 1997; 8: 219A (abstract)
167. Furuland H, Linde T, Danielson B. Physical exercise capacity in patients with end-stage renal disease after normalization of hemoglobin with erythropoietin (EPO). J Am Soc Nephrol 1998; 9: 337A (abstract)
168. Iseki K, Nishime K, Uehara H et al. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 1996; 72: 30-36
169. Evans SJW. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 1997; 76: 116 (letter)
170. Iseki K. Reply to the letter by S. J. W. Evans. Nephron 1997; 76: 117 (letter)
171. Friedlander MA, Hricik DE. Optimizing end-stage renal disease therapy for the patient with diabetes mellitus. Semin Nephrol 1997; 17: 331-345
172. Wakeen M, Zimmerman SW. Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 1998; 32: 488-493
173. Rodgers GP, Dover GJ, Uyesaka N et al. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 1993; 328: 73-80
174. Laudat K, Paulitschke M, Riedel E, Hampl H. Complete correction of renal anemia- no increased risk in access thrombosis or thromboembolic events in hemodialysis patients. J Am Soc Nephrol 1998; 9: 219A (abstract)
175. Boobes Y. Pro-dialysis or post-dialysis hematocrit to monitor EPO treatment? Nephrology 1997; 2: s306 (abstract)
176. Steuer RR, Germain MJ, Leypoldt JK. The variability of predialysis hematocrit during routine hemodialysis is high. Nephrol Dial Transplant 1997; 12: A132 (abstract)
177. Council on Food and Nutrition, Committee on Iron Deficiency. Iron deficiency in the United States. JAMA 1968; 203: 119-124
178. Sakiewicz P, Paganini E. The use of iron in patients on chronic dialysis: mistakes and misconceptions. J Nephrol 1998; 11: 5-15
179. Muller-Wiefel DE, Scigalla P. Specific problems of renal anemia in childhood. Contrib Nephrol 1988; 66: 71-84
180. Longnecker RE, Goffinet JA, Hendler ED. Blood loss during maintenance hemodialysis. Trans Am Soc Artif Intern Organs 1974; 20: 135-141
181. Lindsay RM, Burton JA, Edward N et al. Dialyzer blood loss. Clin Nephrol 1973; 1: 29-34
182. Hoenich NA, Woffindin C, Ronco C. Hemodialysers and associated devices. In: Jacobs C et al, eds. Replacement of renal function by dialysis. Kluwer Academic, Amsterdam: 4th edition 1996: 188-230
183. Müller-Wiefel DE, Sinn H, Gilli G, Schärer K. Hemolysis and blood loss in children with chronic renal failure. Clin Nephrol 1977; 8: 481-486
184. Sunder-Plassmann G, Hörl WH. Erythropoietin and iron. Clin Nephrol 1997; 47: 141-157
185. Jacobs A, Worwood M. Ferritin in serum: clinical and biochemical implications. N Engl J Med 1975; 292: 951-956
186. Macdougall IC, Cavill I, Hulme B et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. Br Med J 1992; 304: 225-226
187. Schaefer RM, Schaefer L. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinat Med 1995; 23: 83-88
188. Braun J, Lindner K, Schreiber M et al. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 1997; 12: 1173-1181
189. Olmer M, Fossat Ch, Bouchouareb D, Purgus R. Hypochromic red cells as a marker of iron deficiency in uremic dialyzed patients receiving r-HuEPO treatment. J Am Soc Nephrol 1997; 8: 206A (abstract)
190. Bainton DF, Finch CA. The diagnosis of iron deficiency anemia. Am J Med 1964; 37: 62-70
191. Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 1991; 57: 175-182
192. Hörl WH, Dreyling K, Steinhauer HB et al. Iron status of dialysis patients under rhuEPO therapy. Contrib Nephrol 1990; 87: 78-86
193. Fishbane S, Lynn RI. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 1995; 44: 238-240
194. Silverberg DS, Iaina A, Peer G et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996; 27: 234-238
195. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996; 7: 2654-2657
196. Tarng D-C, Chen TW, Huang T-P et al. Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 1995; 15: 230-237
197. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-46 (RCT)
198. Silverberg DS, Blum M, Peer G et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72: 413-417
199. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699 (RCT)
200. Granolleras C, Oulès R, Branger B et al. Iron supplementation of hemodialysis patients receiving recombinant human erythropoietin therapy. In: Bauer C et al, eds. Erythropoietin: molecular physiology and clinical applications. Marcel Dekker, Inc., New York: 1993; 211-218
201. Rosenlöf K, Kivivuori SM, Grönhagen-Riska C et al. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol 1995; 43: 249-255
202. Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1079-1083
203. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-2076 (RCT)
204. Sepandj F, Jindal K, West M, Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 1996; 11: 319-322
205. Hörl WH. How to get the best out of r-HuEPO. Nephrol Dial Transplant 1995; 10 (suppl 2): 92-95
206. Sunder-Plassman G, Spilzauer S, Hörl WH. The dilemma of evaluating iron status in dialysis patients limitations of available diagnostic procedures. Nephrol Dial Transplant 1997; 12: 1575-1580
207. Sunder-Plassman G, Hörl WH. Laboratory diagnosis of anemia in dialysis patients: use of common laboratory tests. Curr Opin Nephrol Hypertens 1997; 6: 566-569
208. Kooistra MP, Marx JJM. The management of iron metabolism in recombinant human erythropoietin treated dialysis patients by Dutch nephrologists. Nephrol Dial Transplant 1997; 12: 879-883
209. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995; 25: 433-439 (RCT)
210. Gokal R, Millard PR, Weatherall DJ et al. Iron metabolism in haemodialysis patients: a study of the management of iron therapy and overload. QJM 1979; 48: 369-391
211. Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977; 87: 710-713
212. Milman N. Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. Clin Nephrol 1982; 17: 77-81
213. Donnelly SM, Posen GA, Ali MAM. Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 1991; 14: 271-276
214. Eschbach JW, Cook JD, Finch CA. Iron absorption in chronic renal disease. Clin Sci 1970; 38: 191-196
215. Hughes RT, Smith T, Hesp R et al. Regulation of iron absorption in iron loaded subjects with end stage renal disease: effects of treatment with recombinant human erythropoietin and reduction of iron stores. Br J Haematol 1992; 82: 445-454
216. Skikne BS, Cook JD. Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med 1992; 120: 746-751
217. Johnson CA, Rosowski E, Zimmerman SW. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex®-150 in ESRD patients receiving EPOGEN®. Adv Perit Dial 1992; 8: 444-447
218. Bothwell TH, Pirzio-Biroli G, Finch CA. Iron absorption. I. Factors influencing absorption. J Lab Clin Med 1958: 51: 24-36
219. Tinawi M, Martin KJ, Bastani B. Oral iron absorption test in patients on CAPD: comparison of ferrous sulfate and a polysaccharide ferric complex. Nephron 1996; 74: 291-294
220. Domoto DT, Martin KJ. Failure of CAPD patients to respond to an oral iron absorption test. Adv Perit Dial 1992; 8: 102-104
221. Markowitz GS, Kahn GA, Feingold RE et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997; 48: 34-40 (RCT)
222. Goch J, Birgegåard G, Danielson BG, Wikström B. Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron 1996; 73: 403-406
223. Kooistra MP, Niemantsverdriet EC, van Es A et al. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 1998; 13: 82-88
224. Bergmann M, Grützmacher P, Heuser J, Kaltwasser JP. Iron metabolism under rEPO therapy in patients on maintenance hemodialysis. Int J Artif Organs 1990; 13: 109-112
225. Kooistra MP, van Es A, Struyvenberg A, Marx JJM. Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 1991; 79: 634-639
226. Dunea G, Swagel MA, Bodiwala U, Arruda JAL. Intradialytic oral iron therapy. Int J Artif Organs 1994; 17: 261-264
227. Anastassiades EG, Howarth D, Howarth J et al. Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 1993; 8: 846-853
228. Chander N, Wozniak JS, Rodby R. The economic impact of increased usage of intravenous iron dextran (IVFe) and subcutaneous erythropoietin (SQ EPO) on the total cost of anemia treatment in hemodialysis (HD) patients. J Am Soc Nephrol 1998; 9: 232A (abstract)
229. Nissenson AR, Lindsay RM, Swan S et al. Ferric gluconate (Ferrlecit®) is safe and effective in hemodialysis (HD) patients (PTS): North American Trial. J Am Soc Nephrol 1996; 7: 1459 (abstract)
230. Suh H, Wadhwa NK. Iron dextran treatment in peritoneal dialysis patients on erythropoietin. Adv Perit Dial 1992; 8: 464-466
231. Senger JM, Weiss RJ. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA J 1996; 23: 319-323
232. Schaefer RM, Schaefer L. Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 1992; 3: 71-75
233. Henderson PA, Hillman RS. Characteristics of iron dextran utilization in man. Blood 1969; 34: 357-375
234. Roe DJ, Harford AM, Zager PG et al. Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents. Am J Kidney Dis 1996: 28: 855-860 (RCT)
235. Jabs K, Alexander S, McCabe D et al. Primary results from the U.S. multicenter pediatric recombinant erythropoietin (EPO) study. J Am Soc Nephrol 1994; 5: 456 (abstract) (RCT)
236. Sunder-Plassmann G, Hörl WH. Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1797-1802
237. Hörl WH, Cavill I, Macdougall IC et al. How to diagnose and correct iron deficiency during r-huEPO therapy - a concensus report. Nephrol Dial Transplant 1996; 11: 246-250
238. Navarro JF, Teruel JL, Liano F et al. Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. Am J Nephrol 1996; 16: 268-272
239. Rolla G, Bucca C, Brussino L. Systemic reactions to intraven-ous iron therapy in patients receiving angiotensin converting enzyme inhibitor. J Allergy Clin Immunol 1994; 93: 1074-1075
240. Nyvad O, Danielsen H, Madsen S. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet 1994; 344: 1305-1306 (letter)
241. Pascual J, Teruel JL, Liaño F et al. Serious adverse reactions after intravenous ferric gluconate. Nephrol Dial Transplant 1992; 7: 271-272 (letter)
242. Zanen AL, Adriaansen HJ, van Bommel EFH et al. Oversaturation of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 820-824
243. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-1731
244. Stivelman JC. Optimization of iron therapy in hemodialysis patients treated with rHuEPO. Semin Dial 1994; 7: 288-292
245. St. Peter WL, Lambrecht LJ, Macres M. Randomized crossover study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 523-528 (RCT)
246. Fishbane S, Ungureanu V-D, Maesaka JK et al. Safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-534
247. Kalantar-Zadeh K, Hoff ken B, Wünsch H et al. Diagnosis of iron deficiency anemia in renal failure patients during the posterythropoietin era. Am J Kidney Dis 1995; 26: 292-299
248. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis 1997; 29: 319-333
249. Nissenson AR. Achieving target hematocrit in hemodialysis patients: new concepts in iron management. Am J Kidney Dis 1997; 30: 907-911
250. Drücke TB, Bárány P, Cazzola M et al. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 1997; 48: 1-8
251. Major A, Mathez-Loic F, Rohling R et al. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol 1997; 98: 292-294
252. Akcicek F, Ozhahya M, Cirit M et al. The efficiency of fractionated parenteral iron treatment in CAPD patients. Adv Perit Dial 1997; 13: 109-112
253. Saltissi D, Sauvage D, Westhuyzen J. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Clin Nephrol 1998; 49: 45-48
254. Besarab A, Vogel SE, Abdallah B et al. Maintenance iron dextran in hemodialysis (HD) patients. J Am Soc Nephrol 1997; 8: 228A (abstract)
255. Ahsan N, Groff JA, Waybill MA. Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin. Adv Perit Dial 1996; 12: 161-166
256. Kausz A, Ahmad S, Sherrard D. Effectiveness of intravenous iron in hemodialysis patients: a randomized controlled trial. J Am Soc Nephrol 1997; 8: 220A (abstract) (RCT)
257. Lynn RL, Frei GL, Laitman RS. Weekly low dose intravenous iron dextran (IVFE) improves the erythrogenic response to erythropoietin (EPO) in iron deficient hemodialysis (HD) patients. J Am Soc Nephrol 1997; 8: 221A (abstract)
258. Macdougall IC, Chandler G, Armstrong A et al. Characterization of iron availability from 3 different IV iron preparations in dialysis patients. J Am Soc Nephrol 1997; 8: 22IA (abstract) (RCT)
259. Bayes B, Bonal J, Junca J. Parenteral iron, yes but how? Nephrol Dial Transplant 1998; 13: 230 (letter)
260. Švára F, Sulková S, Kvasnička J, Polakovič V. Iron supplementation during erythropoietin treatment of haemodialyzed patients. Vnitr Lek 1996; 42: 849-852 (RCT)
261. Geleva D, Baugh E, Andrews C et al. Efficacy of frequent dosing of iron dextran on epogen dose and cost on a stable vs mixed maintenance hemodialysis (HD) population. J Am Soc Nephrol 1997; 8: 219A (abstract)
262. Kotaki M, Uday K, Henriquez M et al. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin. Clin Nephrol 1997; 48: 63-64 (letter)
263. Collins A, Ebben J, Ma J, Xia H. Iron dosing patterns and mortality. J Am Soc Nephrol 1998; 9: 205A (abstract)
264. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9: 655-663
265. Souza RM, Defferrari R, Karohl C et al. Iron status evaluation and iron supplementation therapy in hemodialysis (HD) chronic renal failure (CRF) patients: a randomized clinical trial. Nephrology 1997; 2 [suppl 1]: s307 (abstract) (RCT)
266. Cuero CJ, de Rivera C, Pérez GE. Important reduction of the dose of erythropoietin obtained by using parenteral iron. Nephrology 1997; 2 [suppl 1]: s307
267. Lye WC, Chin S, Wong KC, Fan KS. A prospective randomized comparison of three routes of iron administration during erythropoietin therapy in dialysis patients. Nephrology 1997; 2 [suppl 1]: s311 (abstract) (RCT)
268. Al-Hawas F, Abdalla AH, Popovich W et al. Use of i.v. iron saccharate in haemodialysis patients not responding to oral iron and erythropoietin. Nephrol Dial Transplant 1997; 12: 2801-2802 (letter)
269. Sunder-Plassmann G, Hörl WH. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Saf 1997; 17: 241-250
270. Pirzio-Biroli G, Bothwell TH, Finch CA. Iron absorption. II. The absorption of radioiron administered with a standard meal in man. J Lab Clin Med 1958; 51: 24-36
271. Rastogi SP, Padilla F, Boyd CM. Effect of aluminum oxide on iron absorption. Kidney Int 1975; 8: 417 (abstract)
272. Bommer J, Ritz E, Weinreich Th et al. Subcutaneous erythropoietin. Lancet 1988; 2: 406 (letter)
273. McMahon FG, Vargas R, Ryan M et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76: 1718-1722 (RCT)
274. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991; 20: 99-113
275. Brockmöller J, Köchling J, Weber W et al. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol 1992; 34: 499-508
276. Albitar S, Meulders Q, Hammoud H et al. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 1995; 10: 40-43
277. Salmonson T. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin. Scand J Urol Nephrol Suppl 1990; 129: 1-66
278. Çakar N, Ekim M, Turner N et al. Pharmacokinetics of recombinant human erythropoietin in children with chronic renal failure. Int Urol Nephrol 1997; 29: 377-383
279. Schaumann W, Kaufmann B. Subcutaneous versus intravenous epoetin in patients with renal failure. Overview of the pharmacokinetics and comparison with the pharmacodynamic activity. Clin Drug Invest 1997; 13: 270-276
280. Barnas U, Watzinger U, Peer G et al. Subcutaneous versus intravenous administration of human recombinant erythropoietin in patients on chronic hemodialysis. Nefrología 1990; 10: 116-120
281. Besarab A, Flaharty KK, Erslev AJ et al. Clinical pharmacology and economics of recombinant erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992; 2: 1405-1416
282. Bovy C, Dubois B, Popovic A et al. Mode of administration of erythropoietin (rHu-EPO) - does it matter? Nephrol Dialysis Transplant 1995; 10: 1951-1952 (abstract)
283. Bommer J, Barth H-P, Zeier M et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991: 88: 136-143
284. Bommer J, Samtleben W, Koch KM et al. Variations of recombinant human erythropoietin application in hemodialysis patients. Contrib Nephrol 1989; 76: 149-158
285. Boran M, Dalva I, Yazicioǧlu A, Çetin S. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients. Nephron 1993; 63: 113-114 (RCT)
286. Canaud B, Bennhold I, Delons S et al. What is the optimum frequency of administration of r-HuEPO for correcting anemia in hemodialysis patients? Dial Transplant 1995; 24: 306-309 (RCT)
287. Castro MCM, Abensur H, Centeno JR et al. Comparison between thrice-weekly intravenous and once-weekly subcutaneous administration of rHuEPO in hemodialysis patients. Dial Transplant 1994; 23: 132-143
288. Eidemak I, Friedberg MO, Ladefoged SD et al. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD. Nephrol Dial Transplant 1992; 7: 526-529
289. Granolleras C, Branger B, Deschodt G et al. Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients. Contrib Nephrol 1990; 82: 49-54
290. Lim VS, Kirchner PT, Fangman J et al. The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am J Kidney Dis 1989; 14: 496-506 (RCT)
291. McMahon LP, Dawborn JK. Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin. Am J Nephrol 1990; 10: 404-408
292. Morsli R, Morinière P, El Esper N et al. Comparison of s.c. and i.v. rHuEPO in patients on chronic haemodialysis: comparable correction of anaemia with lower doses because of greater bioavailability. Nephrol Dial Transplant 1993; 8: 961 (abstract) (RCT)
293. Muirhead N, Churchill DN, Goldstein M et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol 1992; 12: 303-310 (RCT)
294. Navarro JF, Teruel JL, Marcén R, Ortuno J. Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route. Scand J Urol Nephrol 1995; 26: 11-14
295. Paganini EP, Eschbach JW, Lazarus JM et al. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis 1995; 26: 331-340 (RCT)
296. Parker KP, Mitch WE, Stivelman JC et al. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol 1997; 8: 288-293
297. Schaller R, Sperschneider H, Thieler H et al. Differences in intravenous and subcutaneous application of recombinant human erythropoietin: a multicenter trial. Artif Organs 1994; 18: 552-558 (RCT)
298. Steffensen G, Aunsholt NA, Ahlbom G. Comparative crossover study of intravenously and subcutaneously administered recombinant human erythropoietin in hemodialysis patients. Blood Purif 1992; 10: 241-247 (RCT)
299. Stevens JM, Strong CA, Oliver DO et al. Subcutaneous erythropoietin and peritoneal dialysis. Lancet 1989; 1: 1388-1389 (letter)
300. Vidau P, Peral V, Tomé R et al. Intravenous (i.v.) vs. subcutaneous (s.c.) administration of erythropoietin (EPO) in hemodialysis (HD) patients. Kidney Int 1994; 46: 571 (abstract)
301. Virot JS, Janin G, Guillaumie J et al. Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient? Am J Kidney Dis 1996; 28: 400-408 (RCT)
302. Zehnder C, Blumberg A. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration. Nephron 1991; 57: 485-486
303. Besarab A, Besarab FM, Miller D. Effects of dialysis factors and route of administration on response of hemodialysis patients to recombinant human erythropoietin. ASAIO Trans 1991; 37: M181-M182
304. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. Eur J Clin Pharmacol 1996; 50: 171-177 (RCT)
305. Mondal K, Dressler R, Levine SD, Lynn RI. Comparison of the erythropoietic effects of subcutaneous and intravenous erythropoietin (EPO) in hemodialysis patients. Am J Kidney Dis 1992; 19: A9 (abstract)
306. Stockenhuber F, Loibl U, Gottsauner-Wolf M et al. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 1991; 59: 399-402
307. Taylor JE, Belch JJF, Fleming LW et al. Erythropoietin response and route of administration. Clin Nephrol 1994; 41: 297-302 (RCT)
308. Watson A, Gimenez L, Walser M et al. A prospective double-blind study of subcutaneous recombinant-human erythropoietin in predialysis renal failure. J Clin Pharmacol 1989; 29: 856(abstract) (RCT)
309. Petersen J, Kang MS, Yeh I. The site of injection affects erythropoietin levels during dialysis. ASAIO J 1996; 42: 263-265
310. De Schoenmakere G, Lameire N, Dhondt AM et al. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrol Dial Transplant 1998; 13: 1770-1775
311. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998; 339: 578-583 (RCT)
312. Jorge C, Possante M, Nasamento C et al. Recombinant human erythropoietin intravenous (IV) versus subcutaneous (SC) route. Nephrol Dial Transplant 1996; 11: A264 (abstract)
313. Ortiz M, Pérez García R, Junco E et al. The influence of the route of administration of erythropoietin on its efficiency in patients on chronic hemodialysis: a controlled randomized study. Nephrology 1997; 2 [suppl 1]: s308 (abstract) (RCT)
314. Goodkin DA, Gimenez LF, Graber SE et al. Hematocrit is more stable when epoetin alfa is administered intravenously than subcutaneously to dialysis patients. Nephrol Dial Transplant 1997; 12: A190 (abstract)
315. Domenici A, Ambrosini F, Ferrazzano MT et al. Epoetin for anemia of end stage renal disease: the effect of different schedules of administration and intravenous iron supplementation. Nephrol Dial Transplant 1996; 11: A270 (abstract)
316. Yagil Y, for the Multicenter Study Group, Israel. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Isr J Med Sci 1997; 33: 36-44
317. Yalçinkaya F, Tümer N, Çakar N, Özkaya N. Low-dose eythropoietin is effective and safe in children on continuous ambulatory peritoneal dialysis. Pediatr Nephrol 1997; 11: 350-352
318. Lago M, Pérez-García R, García de Vinuesa MS et al. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients. Nephron 1996; 72: 723-724 (RCT)
319. Frifelt JJ, Tvedegaard E, Bruun K et al. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly. Perit Dial Int 1996; 16: 594-598 (RCT)
320. Stegmayr BG. Better reponse to s.c. erythropoietin in CAPD than HD patients. Scand J Urol Nephrol 1997; 31: 183-187
321. Macdougall IC, Roberts DE, Coles GA, Williams JD. Intraperitoneal erythropoietin. Lancet 1989; 1: 1389 (letter)
322. Bargman JM, Jones JE, Petro JM. The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate. Perit Dial Int 1992; 12: 369-372
323. Reddingius RE, Schröder CH, Koster AM, Monnens LAH. Pharmacokinetics of recombinant human erythropoietin in children treated with continuous ambulatory peritoneal dialysis. Eur J Pediatr 1994; 153: 850-854
324. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000
325. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76-89
326. Scigalla P. Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease. Contrib Nephrol 1991; 88: 201-211
327. Bommer J, Kugel M, Schoeppe W et al. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease. Contrib Nephrol 1988; 66: 85-93 (RCT)
328. Nissenson AR, Korbet S, Faber M et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995; 5: 1517-1529 (RCT)
329. Bennett WM. A multicenler clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1991; 1: 990-998 (RCT)
330. The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991; 18: 50-59 (RCT)
331. Stenvinkel P, Heimbürger O, Lönnqvist F, Bárány P. Does the ob gene product leptin stimulate erythropoiesis in patients with chronic renal failure? Kidney Int 1998; 53: 1430-1431
332. Muirhead N, Hodsman AB. Occult infection and resistance of anaemia to rHuEpo therapy in renal failure. Nephrol Dial Transplant 1990; 5: 232-234
333. Piraino B, Johnston JR. The use of subcutaneous erythropoietin in CAPD patients. Clin Nephrol 1990; 33: 200-202
334. Slingeneyer A, Faller B, Laroche B et al. Self-administered daily subcutaneous recombinant human erythropoietin: an open randomised dose-finding study in ESRD patients receiving peritoneal dialysis. Contrib Nephrol 1991; 88: 159-168
335. Macdougall IC, Coles GA, Williams JD. Inhibition of a response to r-HuEPO in the presence of infection or malignancy. Erythropoiesis 1992; 3: 29-30
336. Sun CH, Ward HJ, Paul WL et al. Serum erythropoietin levels after renal transplantation. N Engl J Med 1989; 321: 151-157
337. Brown JH, Lappin TRJ, Elder GE et al. The initiation of erythropoiesis following renal transplantation. Nephrol Dial Transplant 1996; 4: 1076-1079
338. Besarab A, Caro J, Jarrell BE et al. Dynamics of erythropoiesis following renal transplantation. Kidney Int 1987; 32: 526-536
339. Miles AM, Markell MS, Daskalakis P et al. Anemia following renal transplantation: erythropoietin response and iron deficiency. Clin Transpl 1997; 11: 313-315
340. Nampoory MR, Johny KV, Al-Hilali N et al. Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function. Nephrol Dial Transplant 1996; 11: 177-181
341. Fernández Lucas M, Marcén R, Villafruela J et al. Effect of r-HuEPO therapy in dialysis patients on endogenous erythropoietin synthesis after renal transplantation. Nephron 1996; 73: 54-57
342. Van Loo A, Vanholder R, Bernaert P et al. Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation. Nephrol Dial Transplant 1996; 11: 1815-1821 (RCT)
343. Jindal KK, Hirsch DJ, Belistsky P, Whalen MA. Low-dose subcutaneous erythropoietin corrects the anaemia of renal transplant failure. Nephrol Dial Transplant 1992; 7: 143-146
344. Ettenger RB, Marik J, Grimm P. The impact of recombinant human erythropoietin therapy on renal transplantation. Am J Kidney Dis 1991; 18 [suppl 1]: 57-61
345. Kiberd BA, Belitsky P. The fate of the failed renal transplant. Transplantation 1995; 59: 645-647
346. Yoshimura N, Oka T, Ohmori Y, Aikawa I. Effects of recombinant human erythropoietin on the anaemia of renal transplant rejection. Transplantation 1989; 48: 527-529
347. Kessler M, Legrand E, Mertes M et al. Treatment of chronic renal failure by recombinant erythropoietin and polycythaemia following kidney transplantation. Nephron 1992; 62: 370-371
348. Lezaic V, Djukanovic L, Pavlovic-Kentera V. Recombinant human erythropoietin treatment of anemia in renal transplant patients. Renal Fail 1995; 17: 705-714
349. Vanwallegehem JF, Vanrenterghem YFC. The role of epoetin in predialysis and renal transplantation. Erythropoiesis New Dimens Treat Anaemia 1997; 8: 43-48
350. Almond MK, Tailor D, Marsh FP et al. Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme. Nephrol Dial Transplant 1994: 9: 270-273
351. Donadio JV, Jr, Hart GM, Bergstralh EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995; 4: 109-115
352. Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 1992; 19: 29-35
353. Danielson B. R-HuEPO hyporesponsiveness - who and why? Nephrol Dial Transplant 1995; 10 [suppl 2]: 69-73
354. Drüeke TB. R-HuEPO hyporesponsiveness - who and why? Nephrol Dial Transplant 1995; 10 [suppl 2]: 62-68
355. Douglas SW, Adamson JW. The anemia of chronic disorders: studies of marrow regulation and iron metabolism. Blood 1975; 45: 55-65
356. Hymes LC, Hawthorne SM, Clowers BM. Impaired response to recombinant human erythropoietin therapy in children with peritonitis. Dial Transplant 1994; 23: 462-463
357. Rao DS, Shih M-S, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328: 171-175
358. Grützmacher P, Ehmer B, Limbach J et al. Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism. Blood Purif 1990; 8: 279-284
359. Steffen HM, Brunner R, Müller R et al. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol 1989; 76: 292-298
360. Rosenlöf K, Fyhrquist F, Tenhunen R. Erythropoietin, aluminum, and anaemia in patients on haemodialysis. Lancet 1990; 335: 247-249
361. Muirhead N, Hodsman AB, Hollomby DJ, Cordy PE. The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 1991; 6: 342-345
362. Grützmacher P, Ehmer B, Messinger D et al. Effect of aluminum overload on the bone marrow response to recombinant human erythropoietin. Contrib Nephrol 1989; 76: 315-323
363. Casati S, Passerini P, Campise MR et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 1987; 295: 1017-1020
364. Tomson CRV, Edmunds ME, Chambers K et al. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 1992; 7: 817-821
365. Steinberg MH. Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med 1991; 324: 1369-1370 (letter)
366. Roger SD, Macdougall IC, Thuraisingham RC, Raine AEG. Erythropoietin in anemia of renal failure in sickle cell disease. N Engl J Med 1991; 325: 1175-1176 (letter)
367. Cheng IKP. Lu H, Wei DCC et al. Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. Am J Nephrol 1993; 13: 142-148
368. Lai KN, Wong KC, Li PKT, Lui SF. Use of recombinant erythropoietin in thalassemic patients on dialysis. Am J Kidney Dis 1992; 19: 239-245
369. Drinovec J, Varl J. Subcutaneous erythropoietin in the treatment of renal anaemia. Przegl Lek 1992; 49: 38-40
370. Ono K, Hisasue Y. Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy? Clin Nephrol 1992; 38: 290-292
371. 12 levels after erythropoietin treatment. Am J Nephrol 1992; 12: 188-191
372. 12 supplementation necessary in chronic hemodialysis patients with EPO treatment? Clin Nephrol 1994; 42: 343-345 (letter)
373. Pronai W, Riegler-Keil M, Silberbauer K, Stockenhuber F. Folic acid supplementation improves erythropoietin response. Nephron 1995; 71: 395-400
374. Caillette A, Barreto S, Gimenez E et al. Is erythropoietin treatment safe and effective in myeloma patients receiving hemodialysis? Clin Nephrol 1993; 40: 176-178
375. Taylor JK, Mactier RA, Stewart WK, Henderson IS. Effect of erythropoietin on anaemia in patients with myeloma receiving haemodialysis. Br Med J 1990; 301: 476-477
376. Ruedin P, Pechère Bertschi A, Chapuis B et al. Safety and efficacy of recombinant human erythropoietin treatment of anaemia associated with multiple myeloma in haemodialysed patients. Nephrol Dial Transplant 1993; 8: 315-318
377. Rogers S, Russell NH, Morgan AG. Effect of erythropoietin in patients with myeloma. Br Med J 1990; 301: 667 (letter)
378. Madore F, Bridges K, Brugnara NL et al. A population study of the interplay between iron, nutrition, and inflammation in erythropoiesis in hemodialysis patients. J Am Soc Nephrol 1996; 7: 1456 (abstract)
379. Siimes MA, Rönnholm KAR, Antikainen M, Holmberg C. Factors limiting the erythropoietin response in rapidly growing infants with congenital nephrosis on a peritoneal dialysis regimen after nephrectomy. J Pediatr 1992; 120: 44-48
380. Evers J. Cardiac hemolysis and anemia refractory to erythropoietin: on anemia in dialysis patients. Nephron 1995; 71: 108 (letter)
381. Goicoechea M, Gomez-Campdera F, Polo JR et al. Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy. Clin Nephrol 1996; 45: 420-421 (letter)
382. Mandolfo S, Farina M, Malberti F et al. Parathyroidectomy (PTX) and erythropoietin (rHuEPO) response in anaemic patients with ESRD. Nephrol Dial Transplant 1997; 12: A192 (abstract)
383. Seyrek N, Paydas S, Sagliker Y. Improvement of anemia and secondary hyperparathyroidism with erythropoietin treatment in hemodialysis patients. Nephron 1996; 73: 338-339
384. Rault R, Mangone M. The effect of parathyroidectomy on hematocrit and erythropoietin dose in patients on hemodialysis. ASAIO J 1996; 42: M901-M903
385. Goicoechea M, Vazquez MI, Ruiz MA et al. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialyis patients. Nephron 1998; 78: 23-27
386. Allegra A, Aloisi C, Corica F et al. Erythropoietin-resistant anaemia in haemodialysis patients: investigation and management. Gior Ital Nefrol 1996; 13: 221-226
387. Ifudu O, Chan E, Paul H et al. Anemia severity and missed dialysis treatments in erythropoietin-treated hemodialysis patients. ASAIO J 1996; 43: 146-149
388. Al Shohaib S, Abunijem Z. Intravenous immunoglobulins modify the response to erythropoietin in a CAPD patient. Nephron 1996; 73: 720 (letter)
389. Tzanakis I, Markidou F, Tzimis L et al. Successful trial of steroids in two haemodialysis patients with inflammatory disease and anaemia unresponsive to recombinant erythropoietin. Nephrol Dial Transplant 1996; 11: 400-401
390. Ifudu O, Friedman EA. Economic implications of inadequate response to erythropoietin in patients with end-stage renal disease. Dial Transplant 1997; 26: 664-669
391. Tarng DC, Huang TP. Uraemic pericarditis: a reversible inflammatory state of resistance to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1997; 12: 1051-1054
392. Bárány P, Divino Filho JC, Bergström J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565-568
393. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Inflammation is a major determinant of erythropoietin resistance in dialysis patients. J Am Soc Nephrol 1997; 8: 237A (abstract)
394. Ifudu O, Valcourt JS, Friedman EA. Sepsis provokes an acute drop in hematocrit (HCT) in erythropoietin (EPO)-treated hemodialysis (HD) patients. J Am Soc Nephrol 1997; 8: 238A (abstract)
395. Ifudu O, Matthew JJ, Mayers JD et al. Severity of AIDS and the response to EPO in uremia. Am J Kidney Dis 1997; 30: 28-35
396. Albitar S, Genin R, Fen-Chong M et al. High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 514-518
397. Cleaveland CR. Anemia of chronic disease: a misnomer. Ann Intern Med 1991; 115: 572-573
398. Worrall JC, Allen DA, Raftery MJ, Yaqoob MM. Impaired iron utilization and duration of haemodialysis are principle (sic) factors in erythropoietin resistance. J Am Soc Nephrol 1997; 8: 225A (abstract)
399. Krantz SB. Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 1994; 307: 353-359
400. Pereira BJG. Balance between pro-inflammatory cytokines and their specific inhibitors in patients on dialysis. Nephrol Dial Transplant 1995; 10 [suppl 7]: 27-32
401. Bryl E, Mysliwska J, Debska-Slizien et al. The influence of recombinant erythropoietin on tumor necrosis factor alpha and interleukin-10 production by whole blood cell cultures in hemodialysis patients. Artif Organs 1998; 22: 177-181
402. Ismail N. Use of erythropoietin, active vitamin D3 metabolites, and alkali agents in predialysis patients. Semin Nephrol 1997; 17: 270-284
403. Okuno Y, Takahashi T, Suzuki A et al. Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun 1990; 170: 1128-1134
404. Dessypris E, Graber SE, Krantz SB, Stone WJ. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 1988; 72: 2060-2062
405. Geissler K, Stockenhuber F, Kabrna E et al. Recombinant human erythropoietin and hematopoietic progenitor cells in vivo. Blood 1989; 73: 2229 (letter)
406. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anaemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693-1699
407. Paganini EP, Abdulhadi MH, Garcia J, Magnusson MO. Recombinant human erythropoietin correction of anemia: dialysis efficiency, waste retention, and chronic dose variables. ASAIO Trans 1989; 35: 513-515
408. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334: 420-425
409. Charra B, Calemard E, Ruffet M et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286-1291
410. Onoyama K, Sanai T, Motomura K, Fujishima M. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol 1989; 13 [suppl 3]: S27-S30
411. Sánchez JA. ACE inhibitors do not decrease rHuEPO response in patients with end-stage renal failure. Nephrol Dial Transplant 1995; 10: 1476-1477 (letter)
412. Conlon PJ, Albers F, Butterly D, Schwab SJ. ACE inhibitors do not affect erythropoietin efficacy in haemodialysis patients. Nephrol Dial Transplant 1994; 9: 1359-1360 (letter)
413. Heß E, Sperschneider H, Stein G. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? Nephrol Dial Transplant 1997; 11: 749-751 (letter)
414. Walter J. Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients? Nephrol Dial Transplant 1993; 8: 142 (letter)
415. Dhondt AW, Vanholder RC, Ringoir SMG. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. Nephrol Dial Transplant 1995; 10: 2107-2109
416. Ertürk S, Ates K, Duman N et al. Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: possible implications of angiotensin-converting enzyme inhibitors. Nephrol Dial Transplant 1996; 11: 396-397
417. Morrone LF, Di Paolo S, Logoluso F et al. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Transplantation 1997; 64: 913-918
418. Gossmann J, Thurmann P, Bachmann T et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996; 50: 973-978
419. Abu-Alfa A, Cruz DN, Mahnensmith R et al. ACE inhibitors do not induce Epogen® resistance in hemodialysis patients: a prospective crossover study. J Am Soc Nephrol 1997; 8: 225A (abstract)
420. Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? Am J Kidney Dis 1996; 28: 535-540
421. Albitar S, Genin R, Fen-Chong M et al. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-1210
422. Navarro JE, Macia ML, Mora-Fernandez C et al. Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients. Adv Perit Dial 1997; 13: 257 259
423. Macia M, Mora J, Chahin E, Gallego E et al. Higher erythropoietin (EPO) requirements in peritoneal dialysis patients treated with angiotensin-converting enzyme inhibitors (ACEI). J Am Soc Nephrol 1997; 8: 269A (abstract)
424. Ikeda Y, Sakemi T, Ohtsuka Y et al. Drug-related low responsiveness to recombinant human erythropoietin therapy in three patients with end-stage renal disease. Nephrol Dial Transplant 1997; 12: 371-372
425. Schiffl H. Captopril but not losartan interferes with response to erythropoietin in dialysis patients. J Am Soc Nephrol 1998; 9: 330A (abstract)
426. Schwarzbeck A, Wittenmeier KW, Hällfritzsch U. Anaemia in dialysis patients as a side-effect of sartanes. Lancet 1998; 352: 286
427. Horn S, Holzer H, Horina J. Losartan and renal transplantation. Lancet 1998; 351: 111 (letter)
428. Altun B, Arici M, Yasavul U et al. Role of erythropoietin in pathogenesis of post transplant erythrocytosis (PTE) and mechanism of losartan's efficiency. Nephrol Dial Transplant 1997; 12: 626-627 (letter).
429. Comment on: Ducloux D, Bresson-Vautrin C, Chalopin JM. Effects of angiotensin-receptor antagonists on erythrocytosis after renal transplantation. Nephrol Dial Transplant 1996; 11: 1668
430. Kooistra MP, Struyvenberg A, van Es A. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron 1991; 57: 127-128 (letter)
431. Bérard E, Barrillon D, Iordache A et al. Low dose of L-carnitine impairs membrane fragility of erythrocytes in hemodialysis patients. Nephron 1994; 68: 145 (letter)
432. Bérard E, Iordache A. Effects of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children: about two cases. Nephron 1992; 62: 368-369
433. Labonia WD. L-Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995; 26: 757-764
434. Boran M, Dalva I, Gönenç F, Çetin S. Response to recombinant human erythropoietin (r-HuEPO) and L-carnitine combination in patients with anemia of end-stage renal disease. Nephron 1996; 73: 314-315
435. Kavadias D, Fourtounas C, Tsouchnikas J, Barboutis K. L-carnitine and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis 1996; 28: 156 (letter)
436. Gastaldello K, Vereerstraeten A, Nzame-Nze T et al. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 1995; 10: 44-47
437. Tarng DC, Huang TP. Improvement of anaemia with ascorbic acid in iron-overloaded hemodialysis patients with hyporesponsiveness to erythropoeitin. Nephrology 1997; 3 [suppl 1]: s189
438. Pronai W. Folic acid supplementation improves erythropoeitin response. Nephron 1997; 76: 120 (letter)
439. Cristol J-P, Bosc J-Y, Badiou S et al. Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 1997; 12: 2312-2317
440. Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992; 37: 264-267 (RCT - incomplete randomization)
441. Ballal SH, Domoto DT, Polack DC et al. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17: 29-33
442. Teruel JL, Marcen R, Navarro-Antolin J. et al. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study. J Am Soc Nephrol 1996; 7: 140-144
443. Teruel JL, Aguilera A, Marcen R et al. Androgen therapy for anaemia of chronic renal failure. Scand J Urol Nephrol 1996; 30: 403-408
444. Gaughan WJ, Liss KA, Dunn SR et al. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 1997; 30: 495-500
445. Fourtounas C, Tzanatos H, Fourtounas C et al. Androgens, erythropoietin, iron stores and lipoprotein(a) in hemodialysis patients. Am J Kidney Dis 1997; 30: 935-936
446. Saxena S, Dash SC, Tiwari SC et al. Effect of nandrolone decanoate on response to low dose erythropietin (EPO) in anemia of end stage renal disease (ESRD) patients on maintendance hemodialysis (MHD). Nephrology 1997; 2 [suppl 1]: s310 (abstract)
447. Audet A-M, Goodnough LT. Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116: 403-406
448. Hædersdal C, Mehlsen J, Stenver D et al. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure. Angiology 1994; 45: 231-234
449. Nomoto Y, Kawaguchi Y, Kubota M et al. A multicenter study with once a week or once every two weeks high-dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis. Perit Dial Int 1994; 14: 56-60
450. Pais MJ, Gaspar A, Santana A et al. Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13 [suppl 2]: S541-S543
451. Buccianti G, Colombi L, Battistel V. Use of recombinant human erythropoietin (rh-EPO) in the treatment of anemia in hemodialysis patients: a multicenter Italian experience. Haematologica 1993; 78: 111-117
452. Bárány P, Pettersson E, Konarski-Svensson JK. Long term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transplant 1993; 8: 426-432
453. Roger SD, Baker LRI, Raine AEG. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO). Clin Nephrol 1993; 39: 103-110
454. Stefanidis CJ, Koulieri A, Siapera D et al. Effect of the correction of anemia with recombinant human erythropoietin on growth of children treated with CAPD. Adv Perit Dial 1992; 8: 460-463
455. Frenken LAM, Struijk DG, Coppens PJW et al. Intraperitoneal administration of recombinant human erythropoietin. Perit Dial Int 1992; 12: 378-383
456. Pascual J, Teruel JL, Marcén R et al. Blood pressure after three different forms of correction of anemia in hemodialysis. Int J Artif Organs 1992; 15: 393-396
457. Piazza V, Villa G, Galli F et al. Erythropoietin as treatment of haemodialysis-related porphyria cutanea tarda. Nephrol Dial Transplant 1992; 7: 438-442
458. Stevens ME, Summerfield GP, Hall AA et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. Br Med J 1992; 304: 474-477
459. Takayama K, Nagai T, Kinugasa E et al. Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients. ASAIO Trans 1991; 37: M183-M188
460. Bianchetti MG, Hämmerli I, Roduit C et al. Epoetin alfa in anaemic children or adolescents on regular dialysis. Eur J Pediatr 1991; 150: 509-512
461. Bajo MA, Selgas R, Miranda B et al. Medium term response to H-R erythropoietin in CAPD patients: the influence of erythropoietin plasmatic levels and the effects on peritoneal transport capacity. Adv Perit Dial 1991; 7: 296-300
462. Saleh A, Krane NK, Caballero M, Starks E. Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD. Adv Perit Dial 1991; 7: 288-291
463. Lye WC, Lee EJC. Subcutaneous recombinant human erythropoietin in patients on CAPD. Adv Perit Dial 1991; 7: 285-287
464. Tsai J-C, Lai Y-H, Tsai Z-Y et al. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1991; 7: 126-135
465. Ramírez B, Flores A, Pérez F et al. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment. Transplant Proc 1991; 23: 1833-1834
466. Canadian Erythropoietin Study Group. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Am J Nephrol 1991; 11: 23-26 (RCT)
467. Lai KN, Lui SF, Leung JCK et al. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 1991; 57: 394-400
468. Lubrich-Birkner I, Schollmeyer P, Steinhauer HB. One year experience with subcutaneous human erythropoietin in CAPD: correction of renal anemia and increased ultrafiltration. Adv Perit Dial 1990; 6: 302-307
469. Bárány P, Pettersson E, Bergström J. Erythropoietin treatment improves quality of life in hemodialysis patients. Scand J Urol Nephrol Suppl 1990; 131: 55-60
470. Offner G, Hoyer PF, Latta K et al. One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis. Pediatr Nephrol 1990; 4: 498-500
471. Edmunds ME, Walls J, Tucker B et al. Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989; 4: 1065-1069
472. Onoyama K, Kumagai H, Takeda K et al. Effects of human recombinant erythropoietin on anaemia, systemic haemodynamics and renal function in predialysis renal failure patients. Nephrol Dial Transplant 1989; 4: 966-970
473. Steinhauer HB. Effects of long-term treatment with human recombinant erythropoietin in patients on CAPD. Adv Exp Med Biol 1989: 157-165
474. Lui SF, Chung WWM, Leung CB et al. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1990; 33: 47-51
475. Vaziri ND, Ritchie C, Brown P et al. Effect of erythropoietin administration on blood and plasma viscosity in hemodialysis patients. ASAIO Trans 1989; 35: 505-508
476. Pollok M, Bommer J, Gurland HJ et al. Effect of recombinant human erythropoietin treatment in end-stage renal failure patients: results of a multicenter phase II/III study. Contrib Nephrol 1989; 76: 201-211 (RCT)
477. Samtleben W, Baldamus CA, Bommer J et al. Indications and contraindications for recombinant human erythropoietin treatment: results in hemodialysis patients. Contrib Nephrol 1989; 76: 193-200
478. Suzuki M, Hirasawa Y, Hirashima K et al. Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Contrib Nephrol 1989; 76: 179-192 (RCT)
479. Nielsen OJ, Thaysen JH. Response to erythropoietin in anaemic haemodialysis patients. J Intern Med 1989; 226: 89-94
480. Verbeelen D, Hauglustaine D, Sennesael J. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin. Neth J Med 1988; 33: 60-67
481. Drücke T, Zins B, Naret C et al. Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure. Adv Nephrol Necker Hosp 1989; 18: 187-206
482. Zehnder C, Glück Z, Descoeudres C et al. Human recombinant erythropoietin in anaemic patients on maintenance haemodialysis: secondary effects of the increase of haemoglobin. Nephrol Dial Transplant 1988; 3: 657-660
483. Bommer J, Alexiou C, Müller-Bühl U et al. Recombinant human erythropoietin therapy in haemodialysis patients dose determination and clinical experience. Nephrol Dial Transplant 1987; 2: 238-242
484. Faller B, Slingeneyer A, Waller M et al. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study. Clin Nephrol 1993; 40: 168-175
485. Eschbach JW, Davidson RC. Red blood cell mass/erythropoietin and blood pressure: lessons from patients with renal disease. In: Laragh JH and Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management. 24. Raven Press, Ltd, New York: 2nd edition 1995: 389-398
486. Maschio G. Erythropoietin and systemic hypertension. Nephrol Dial Transplant 1995; 10 [suppl 2]: 74-79
487. Iorio L, Saltarelli G, Nacca RG, Violi F. Relation between blood pressure and hematocrit in anephric patients treated by means of recombinant DNA human erythropoietin. Nephron 1996; 72: 373-374
488. Zhou XJ, Pandian D, Wang XQ, Vaziri ND. Erythropoietin-induced hypertension in the rat is not mediated by alterations in plasma endothelin, vasopressin, or atrial natriuretic peptide levels. J Am Soc Nephrol 1997; 8: 901-905
489. Hand MF, Haynes WG, Johnstone HA et al. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995; 48: 806-813
490. Vaziri ND, Zhou XJ, Naqvi F et al. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 1996; 271: E113-E122
491. Bode-Böger S, Kuhn M, Radermacher J, Frölich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996; 50: 1255-1261
492. Takagi N, Kihara M, Yabana M et al. Influence of age and renin-aldosterone (RA) system on blood pressure in hemodialysis (HD) patients with erythropoietin (EPO) treatment. Nephrology 1997; 2 [suppl 1]: s305 (abstract)
493. Dorhout Mees EJ, Ok E. Erythropoietin hypertension: fact or fiction? Int J Artif Organs 1997; 20: 415-417
494. Nurol A, Bahattin A, Togla K et al. Acute effect of erythropoietin on endothelin release in uremia. Nephron 1996; 72: 728-729 (letter)
495. Kammoun K, Morinière Ph, Drochon A et al. Rheological and hypertensive effects of erythropoietin treatment. J Am Soc Nephrol 1997; 8: 240A (abstract)
496. Langenfeld MRW, Veelken R, Schobel HP et al. Is endogenous erythropoietin a pathogenetic factor in the development of essential hypertension? Nephrol Dial Transplant 1997; 12: 1155-1160
497. Mann JFE. Hypertension and cardiovascular effects long-term safety and potential long-term benefits of r-HuEPO. Nephrol Dial Transplant 1995; 10 [suppl 2]: 80-84
498. Lameire N, Vanholder RC, Van Loo A et al. Cardiovascular diseases in peritoneal dialysis patients: the size of the problem. Kidney Int 1996; 50 [suppl 56]: s28-s36
499. Allegra V, Martimbianco L, Mengozzi G, Vasile A. Erythropoietin and cardiovascular risk. Blood Purif 1995; 13: 301-313
500. Bajo MA, Selgas R, Castro MJ et al. Erythropoietin treatment decreases cardiovascular morbidity and mortality in CAPD patients. Peritoneal Dial Int 1997; 17: 129-135
501. Delanty N, Vaughan C, Frucht S, Stubgen P. Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology 1997; 49: 686-689
502. Viganò G, Noris M, Remuzzi G. Coagulation disorders in the patient with failing renal function. In: Davidson AM et al., eds. Oxford textbook of clinical nephrology. Oxford University Press, Oxford, 1997; 1989-1995
503. Ambuhl PM, Wuthrich RP, Korte W et al. Plasma hypercoagulability in hemodialysis patients: impact of dialysis and anticoagulation. Nephrol Dial Transplant 1997; 12: 2355-2364
504. Jaar B, Denis A, Viron B et al. Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation. Am J Nephrol 1997; 17: 399-405
505. Borawski J, Rydzewski A, Mazerska M et al. Inverse relationship between haemoglobin and ristocetin-induced platelet aggregation in hemodialysis patients under erythropoietin therapy. Nephrol Dial Transplant 1996; 11: 2444-2448
506. Clyne N, Lins LE, Egberg N. Long-term effects of erythropoietin treatment on the coagulation system during standardised hemodialysis. Clin Nephrol 1995; 43: 260-267
507. Rivas JM, Pérez García A, Möll R, Cervero A. A direct action of recombinant human erythropoietin (r-HuEPO) on platelet function in uremic patients on hemodialysis. Nefrología 1996; 16: 46-53
508. Malyszko JS, Malyszko J, Pawlak K, Mysliwiec M. Erythropoietin and uremic platelet aggregation in vivo and in vitro. Int J Clin Lab Res 1996; 26: 199-202
509. Livio M, Marchesi D, Remuzzi G et al. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2: 1013-1015
510. Kuriyama S, Hopp L, Yoshida H et al. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am J Hypertens 1996; 9: 426-431
511. De Marchi S, Cecchin E, Falleti E et al. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 1997; 8: 1147-1156 (RCT)
512. Nagai T, Akizawa T, Kohjiro S et al. rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells. Kidney Int 1996; 50: 102-107
513. Lazarus JM, Hakim RM, Newell J. Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients. Am J Kidney Dis 1990; 16: 101-108
514. Duff DR, Golper TA, Sloan RS et al. Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients. Am J Kidney Dis 1991; 18: 60-64
515. Fischer-Colbrie W, Clyne N et al. The effect of erythropoietin treatment on arteriovenous haemodialysis fistula/graft: a prospective study with colour flow Doppler ultrasonography. Eur J Vasc Surg 1994; 8: 346-350
516. Shand Bl, Buttimore AL, Hurrell MA et al. Hemorheology and fistula function in home hemodialysis patients following erythropoietin treatment: a prospective placebo-controlled study. Nephron 1993; 64: 53-57 (RCT)
517. Eschbach JW, Aquiling T, Haley NR et al. The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 1992; 38 [suppl 1]: S98-S103
518. Wirtz JJJM, van Esser JWJ, Hamulyák K et al. The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients. Clin Nephrol 1992; 38: 277-282
519. Bahlmann J, Schöter K-H, Scigalla P et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol 1991; 88: 90-106
520. Samtleben W, Ehmer B, Lutz-Knochenhauer I et al. Side effects during recombinant human erythropoietin therapy in 2,000 ESRD patients. Contrib Nephrol 1991; 88: 107-116
521. Fabris F, Cordiano I, Randi ML et al. Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by haemodialysis. Pediatr Nephrol 1991; 5: 225-228
522. Delano BG, Lundin AP, Galonsky R et al. Dialyzer urea and creatinine clearances are not significantly altered in erythropoictin treated maintenance hemodialysis patients. ASAIO Trans 1990; 36: 36-39
523. Canaud B, Polito-Bouloux C, Garred LJ et al. Recombinant human crythropoietin: 18 months' experience in hemodialysis patients. Am J Kidney Dis 1990; 15: 169-175
524. Schaefer RM, Kuerner B, Zech M et al. Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin. Int J Artif Organs 1988; 11: 249-254
525. Klinkmann H, Wieczorek L, Scigalla P. Adverse events of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study. Artif Organs 1993; 17: 219-225
526. Muirhead N. Erythropoietin is a cause of access thrombosis. Semin Dial 1993; 6: 184-188
527. Churchill DN, Muirhead N, Goldstein M et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 1994; 4: 1809-1813
528. Roth DA, Ciampaglia SK, Benjamin J. Effect of hemoglobin (Hb) and erythropoietin (Epo) dosage on prosthetic arteriovenous access graft (PAVG) survival. J Am Soc Nephrol 1997; 8: 170A (abstract)
529. Sreedhara R, Himmelfarb J, Lazarus M et al. Anti-platelet therapy in graft thrombosis: resuslt of a prospective double blind study. Kidney Int 1994; 45: 1477-1483 (RCT)
530. Johnson WJ, McCarthy JT, Yanagihara T et al. Effect of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability. Kidney Int 1990; 38: 919-924
531. Laupacis A. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. Semin Nephrol 1990; 10: 11-19
532. Krantz SB. Review of patients' responses to epoetin alfa therapy. Pharmacotherapy 1990; 10: 15S-21S
533. Schaefer RM, Schaefer L. Treatment with erythropoietin and loss of dialyzer clearance. Nephrol Dial Transplant 1996; 11 [suppl 2]: 81-82
534. Kes P, Reiner Z, Starcevic B, Ratkovic-Gusic I. Influence of erythropoietin treatment on dialyzer reuse. Blood Purif 1997; 15: 77-83
535. Prabhakar SS, Muhlfelder T. Antibodies to recombinant erythropoetin causing pure red cell aplasia. Clin Nephrol 1997; 47: 331-335
536. Montagnac R, Boffa GA, Schillinger F, Guillaumie J. Sensibilisation à l'erythropoietine humaine récombinante chez une hémodialysée. Presse Med 1992; 21: 84-85
537. Bergrem H, Danielson BG, Eckardt KU et al. A case of erythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer C et al, eds. Erythropoietin: molecular physiology and clinical applications. Marcel Dekker Inc., New York: 1988: 265-273
538. Macdougall IC. Merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant 1998; 13: 847-849
539. Hörl WH. Measurement of hypochromic red blood cells is not the first line procedure to identify the patient with iron deficiency. Nephrol Dial Transplant 1998; 13: 850-851
540. Brock JH. Iron in infection, immunity, inflammation and neoplasia. In: Brock JH et al, eds. Iron metabolism in health and disease. WB Saunders, Baltimore: 1994: 360-382
541. Jonnalagadda V, Bloom EJ, Raja RM. Importance of iron saturation for erythropoietin responsiveness in chronic peritoneal dialysis. Adv Perit Dial 1997; 13: 113-115
542. Ahluwalia N, Skikne BS, Savin V, Chonko A. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis 1997; 30: 532-541
543. Kalantar-Zadeh K, Kleiner M, Dunne E et al. Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 1998; 31: 263-272
544. Mittman N, Sreedhara R, Mushnik R et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997; 30: 912-922
545. Bhandari S, Norfolk D, Brownjohn A, Turney J. Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy. Am J Kidney Dis 1997; 30: 814-821
546. Bhandari S, Brownjohn AM, Turney JH. Changes in CHr in response to intravenous iron therapy in haemodialysis patients. J Am Soc Nephrol 1998; 9: 243A (abstract)
547. Mittman N, Sreedhara R, Thomas A et al. Prospective evaluation of reticulocyte hemoglobin content (CHr) to predict functional iron deficiency in hemodialysis (HD). J Am Soc Nephrol 1998; 9: 262A (abstract)
548. Fishbane S, Lynn RI. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 1995; 25: 426-432
549. Braun J, Hammerschmidt M, Schreiber M et al. Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialyis patients? Nephrol Dial Transplant 1996; 11: 492-497
550. Baldus M, Salopek S, Möller M et al. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialyis patients. Nephrol Dial Transplant 1996; 11: 486-491
551. De Paoli Vitali E, Ricci G, Perini L et al. The determination of plasma transferrin receptor as a good index of erythropoietic activity in renal anemia after renal transplantation. Nephron 1996; 72: 552-556
552. Mizuguchi T, Minakuchi J, Kawahara K et al. Serum transferrin receptor level as an index of the response to erythropoietin therapy for anemia in pre-dialysis patients with chronic renal failure. Jpn J Nephrol 1997; 39: 497-502
553. Teruel JL, Villafruela JJ, Navarro J et al. Serum transferrin receptor in patients on hemodialysis. Nefrología 1997; 17: 166-170
554. Halkett JA, Levey MJ, Van Zyl-Smit R. Transferrin receptor levels in haemodialysis patients. Nephrology 1997; 2 [suppl 1]: s312 (abstract)
555. Longmate R, Davenport A, Smith N. Serum transferrin receptors (sTfr) are not useful as markers of functional iron deficiency in haemodialysis patients. J Am Soc Nephrol 1998; 9: 218A (abstract)
556. Bárány P, Eriksson LC, Hultcrantz R et al. Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metabol 1997; 23: 273-276
557. Eschbach JW, Adamson JW. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int 1999; 55 (suppl 69): S35-S43.
558. Hakim RM, Stivelman JC, Schulman G et al. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 1987; 10: 293-299
559. Stivelman J, Schulman G, Fosburg M et al. Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients. Kidney Int 1989; 36: 1125-1132
560. Schafer AI, Cheron RG, Dluhy R et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304: 319-324
561. Ali M, Fayemi AO, Rigolosi R et al. Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases. JAMA 1980; 244: 343-345
562. Van de Vyver FL, Vanheule AO, Verbeuken AH et al. Patterns of iron storage in patients with severe renal failure. Contrib Nephrol 1984; 38: 153-166
563. Bregman H, Gelfand MC, Winchester JF et al. Iron-overload-associated myopathy in patients on maintenance haemodialysis: a histocompatibility-linked disorder. Lancet 1980; 2: 882-885
564. Tielemans CL, Lenclud CM, Wens R et al. Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 1989; 4: 883-887
565. Ward CG, Bullen JJ, Rogers HJ. Iron and infection: new developments and their implications. J Trauma 1996; 41: 356-364
566. Weinberg ED. Iron withholding: a defense against infection and neoplasia. Physiol Rev 1984; 64: 65-102
567. Seifert A, von Herrath D, Schaefer K. Iron overload, but not treatment with desferrioxaminc favours the development of septicemia in patients on maintenance hemodialysis. QJM 1987; 65: 1015-1024
568. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995; 10: 377-381
569. Cantinieaux B, Boelaert J, Hariga C, Fondu P. Impaired neutrophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis. J Lab Clin Med 1988; 111: 524-528
570. Flament J, Goldman M, Waterlot Y et al. Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 1986; 25: 227-230
571. Hershko C, Peto TEA, Weatherall DJ. Iron and infection. Br Med J 1988; 296: 660-664
572. Boelaert JR, Daneels RF, Schurgers ML et al. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990; 5: 130-134
573. Waterlot Y, Cantinieaux B, Hariga-Muller C et al. Impaired phagocytic activity of neutrophils in patients receiving hemodialysis: the critical role of iron overload. Br Med J 1985; 291: 501-504
574. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-876
575. Klein HG. Immunologic aspects of blood transfusion. Semin Oncol 1994; 21: 16-20
576. Boelaert JR, Cantinieaux BF, Hariga CF, Fondu PG. Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 1990; 5: 504-507